Dr Martens grew too fast after its IPO — and lost 80% of its value

Dr Martens listed on the London Stock Exchange in January 2021 at 370p per share, valuing the company at £3.7 billion. The IPO gave the brand a global platform and ambitious growth targets. Management pushed aggressively into the US market, expanding wholesale distribution and opening new stores. But the expansion was executed poorly — the company misread US demand, built up excess inventory, and had to resort to heavy discounting to clear stock.

The discounting eroded the brand's premium positioning and margins. Revenue fell from £1 billion in FY2023 to £877 million in FY2024 (down 12.3%), and pre-tax profit collapsed 41.7% to £93 million. The next year was worse — sales fell further to £765 million and pre-tax profit plunged to around £28 million, a 69% decline. Dr Martens issued five profit warnings in total. The stock, which had been priced at 370p at IPO, lost more than 80% of its value.

CEO Kenny Wilson, who had led the company for six years, stepped down in 2024 and was replaced by chief brand officer Ije Nwokorie in January 2025. The new CEO's strategy focused on tightening discount control, cutting costs, and restoring the brand's premium image. By 2026, Dr Martens reported a return to profit growth after reducing promotions. But the damage was lasting: the company that had been worth £3.7 billion at IPO was now valued at a fraction of that, and the brand's rebellious cachet — carefully cultivated over 60 years — had been eroded by years of discounting.